Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
117 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Gyre Therapeutics, Inc.’s names, not what it holds today.
Patents granted
117
116 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
109
1 of them in 2025
Names they are printed under
6
a former name, a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Targacept, Inc. a former name
US, as the owner printed on each patent
73 publishedCatalyst Biosciences, Inc. a former name
US, as the owner printed on each patent
1 publishedCatalyst Biosciences, Inc. a former name
named as the applicant on its applications, in US
18 publishedTargacept, Inc. a former name
named as the applicant on its applications, in US
13 publishedBEIJING CONTINENT PHARMACEUTICALS CO., LTD a subsidiary
named as the applicant on its applications, in CN
3 publishedGyre Therapeutics, Inc. its own name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 8, 2022 | 11,491,212 | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Aug 2, 2022 | 11,401,513 | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Mar 8, 2022 | 11,266,724 | Modified factor VII polypeptides for subcutaneous administration and on-demand treatment | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Dec 21, 2021 | 11,203,749 | Factor VII polypeptides that are modified and uses thereof | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Apr 20, 2021 | 10,982,203 | Modified factor IX polypeptides and uses thereof | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Mar 23, 2021 | 10,954,501 | Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Sep 22, 2020 | 10,781,435 | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Jul 21, 2020 | 10,716,770 | Nicotinic receptor non-competitive antagonists | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Apr 16, 2019 | 10,258,582 | Nicotinic receptor non-competitive antagonists | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Dec 25, 2018 | 10,160,961 | Factor VII polypeptides that are modified and uses thereof | Pharmaceuticals | Catalyst Biosciences, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 9, 2025 | 2025/0313593 | DIPEPTIDE DERIVATIVE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Pharmaceuticals | BEIJING CONTINENT PHARMACEUTICALS CO., LTD |
| Aug 22, 2024 | 2024/0277682 | PHARMACEUTICAL HYDRONIDONE FORMULATIONS FOR DISEASES | Pharmaceuticals | Gyre Therapeutics, Inc. |
| Aug 8, 2024 | 2024/0261271 | APPLICATION OF HYDRONIDONE IN PREPARATION OF DRUG FOR TREATING OR PREVENTING CHRONIC HEPATITIS B WITH LIVER FIBROSIS | Pharmaceuticals | BEIJING CONTINENT PHARMACEUTICALS CO., LTD |
| Mar 2, 2023 | 2023/0068020 | MACROLIDE COMPOUND AND ITS USE OF TREATMENT CHRONIC RESPIRATORY DISEASE | Organic fine chemistry | BEIJING CONTINENT PHARMACEUTICALS CO., LTD |
| Feb 9, 2023 | 2023/0038638 | COMPLEMENT FACTOR I-RELATED COMPOSITIONS AND METHODS | Biotechnology | Catalyst Biosciences, Inc. · patent 12,116,606 granted from it |
| Nov 18, 2021 | 2021/0355474 | MODIFIED MEMBRANE TYPE SERINE PROTEASE 1 (MTSP-1) POLYPEPTIDES AND METHODS OF USE | Pharmaceuticals | Catalyst Biosciences, Inc. · patent 11,807,882 granted from it |
| Aug 5, 2021 | 2021/0238260 | GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES | Biotechnology | Catalyst Biosciences, Inc. |
| Jul 29, 2021 | 2021/0230570 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF | Pharmaceuticals | Catalyst Biosciences, Inc. |
| Jul 22, 2021 | 2021/0222143 | MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE | Biotechnology | Catalyst Biosciences, Inc. · patent 11,613,744 granted from it |
| Jun 24, 2021 | 2021/0187083 | MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT | Pharmaceuticals | Catalyst Biosciences, Inc. · patent 11,266,724 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.